DDIT4 and neoplasm: Based on the above experiments showing the benefits of DDIT4‐AS1 knockdown in sensitizing tumor cells to paclitaxel, we next designed and fabricated a nano‐based system that can codeliver paclitaxel and DDIT4‐AS1 siRNA to tumors.